BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation Gilti Percent
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation Gilti Percent of 2.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation gilti percent for fiscal 2025 was 2.40%.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation gilti percent for fiscal 2024 was -6.00%, a 330.77% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation gilti percent for fiscal 2023 was 2.60%, a 68.29% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation gilti percent for fiscal 2022 was 8.20%, a 2.50% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation Gilti Percent 12 month |
|---|---|
| 2025-12-31 | 2.40% 10-K · filed 2026-02-11 |
| 2024-12-31 | -6.00% 10-K · filed 2026-02-11 |
| 2023-12-31 | 2.60% 10-K · filed 2026-02-11 |
| 2022-12-31 | 8.20% 10-K · filed 2025-02-12 |
| 2021-12-31 | 8.00% 10-K · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |